Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Somatostatin analogs (SSAs) are typically used to treat the symptoms caused by neuroendocrine tumors (NETs), but they are not used as the primary treatment to induce tumor shrinkage. We report a case of a 63-year-old woman with a symptomatic metastatic NET of the ileum. Complete symptomatic response was achieved after 1 month of treatment with SSAs. In addition, there was an objective response in the liver, with the disappearance of secondary lesions noted on computed tomography scan after 3 months of octreotide treatment. Our experience suggests that SSAs could be useful for downstaging and/or downsizing well-differentiated NETs, and they could allow surgery to be performed. Such presurgery therapy could be a promising tool in the management of patients with initially inoperable NETs.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4386800 | PMC |
| http://dx.doi.org/10.2147/OTT.S71025 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Management of chylous pleural and peritoneal effusions in a cirrhotic patient: A case report and review of literature.
J Int Med Res
September 2025
Department of General Medicine, People's Hospital of Garze Tibetan Autonomous Prefecture, China.
This case report details the management of a patient with cirrhosis who developed chylous pleural and peritoneal effusions. The patient, with a 28-year history of untreated hepatitis B, presented with dyspnea and cough after traveling to a high-altitude area. Imaging and laboratory tests confirmed the presence of chylous effusions.
View Article and Find Full Text PDFMcCune-Albright syndrome with multiple hyperfunctional endocrinopathies: diagnosis, treatment, and long-term follow-up: a case report.
Front Endocrinol (Lausanne)
September 2025
Pediatric Endocrinology Department, Obesity, Endocrine and Metabolism Center, King Fahd Medical City, Riyadh, Saudi Arabia.
McCune-Albright syndrome (MAS) is a rare genetic disorder characterized by a triad of café-au-lait spots, fibrous dysplasia, and hyperfunctioning endocrinopathies, resulting from a mosaic mutation in the guanine nucleotide-binding protein (GNAS) gene. This case report presents the long-term follow-up of an eight-year-old girl diagnosed with MAS, who first presented at 22 months of age with skin pigmentation, hyperthyroidism, and precocious puberty, later developing additional features such as fibrous dysplasia and growth hormone excess. This complex presentation of MAS-featuring more than two hyperfunctioning endocrinopathies along with fibrous dysplasia-has rarely been described in the literature.
View Article and Find Full Text PDFPurpose: Patients with advanced, well-differentiated extrapancreatic neuroendocrine tumors (epNETs) have limited systemic treatment options. Pazopanib, an oral multikinase inhibitor with activity against vascular endothelial growth factor receptor (VEGFR)-2 and -3, PDGFR-alpha and-beta, and c-Kit, was tested for efficacy in epNET.
Patients And Methods: We conducted a multicenter, randomized, double-blind, phase II study of pazopanib (800 mg once daily) versus placebo in low- to intermediate-grade epNET with radiologic progressive disease (PD) within 12 months of study entry.
Diagnostic characteristics, treatment outcomes, and prognostic factors in glucagonomas.
Endocr Oncol
January 2025
Neuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal Free Hospital NHS Trust, London, United Kingdom.
Objective: Glucagonomas are rare islet cell tumours, accounting for 2% of such tumours, with an annual incidence of 0.01-0.1 per million.
View Article and Find Full Text PDFSuccessful treatment of chylous leakage with delayed presentation after endometrial cancer surgery using dietary therapy, octreotide, and computed tomography-guided lymphangiography: A case report and literature review.
J Obstet Gynaecol Res
September 2025
Department of Obstetrics and Gynecology, Federation of National Public Service Personnel Mutual Aid Associations, Tachikawa Hospital, Tokyo, Japan.
Objective: Chylous ascites (CA) is a rare yet clinically significant complication following gynecologic cancer surgery, with incidence rates of 0.17 % to 9%. We aimed to describe a case of CA with a delayed clinical presentation nearly 100 days postoperatively in a patient with advanced endometrial cancer and to review the management strategies.
View Article and Find Full Text PDF